Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT.
Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL. Tizon R, et al. Among authors: vogl d. Bone Marrow Transplant. 2012 Oct;47(10):1332-7. doi: 10.1038/bmt.2011.260. Epub 2012 Feb 6. Bone Marrow Transplant. 2012. PMID: 22307018 Clinical Trial.
S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes.
Lin C, Garcia-Gerique L, Bonner EE, Mastio J, Rosenwasser M, Cruz Z, Lawler M, Bernabei L, Muthumani K, Liu Q, Poncz M, Vogl T, Törngren M, Eriksson H, Vogl DT, Gabrilovich DI, Nefedova Y. Lin C, et al. Among authors: vogl dt. Cancer Res Commun. 2023 Mar 13;3(3):420-430. doi: 10.1158/2767-9764.CRC-22-0368. eCollection 2023 Mar. Cancer Res Commun. 2023. PMID: 36923707 Free PMC article.
Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy.
Tang Y, Liu W, Kadu S, Johnson O, Hasanali ZS, Kelly A, Shestov A, Pajarillo R, Greenblatt E, Holmes M, Wang LP, Shih N, O'Connor RS, Ruella M, Garfall AL, Allman D, Vogl DT, Cohen A, June CH, Sheppard NC. Tang Y, et al. Among authors: vogl dt. Blood. 2024 Jan 11;143(2):139-151. doi: 10.1182/blood.2022018658. Blood. 2024. PMID: 37616575 Free PMC article.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Benboubker L, et al. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. N Engl J Med. 2014. PMID: 25184863 Free article. Clinical Trial.
Medical management update: multiple myeloma.
Stoopler ET, Vogl DT, Stadtmauer EA. Stoopler ET, et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 May;103(5):599-609. doi: 10.1016/j.tripleo.2006.10.026. Epub 2007 Feb 7. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007. PMID: 17291793
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA. Vogl DT, et al. Am J Hematol. 2007 Dec;82(12):1071-5. doi: 10.1002/ajh.21038. Am J Hematol. 2007. PMID: 17696204 Free article.
131 results